C07D 217/00
Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
C07D217/00 (Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems) appears on 3,310 US grants and 3,035 published applications in this corpus.
Search patents in C07D- Granted patents
- 3,310
- Published applications
- 3,035
- Assignees
- 1,364
- Inventors
- 10,135
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 42 | 0 |
| 1977 | 48 | 0 |
| 1978 | 51 | 0 |
| 1979 | 21 | 0 |
| 1980 | 30 | 0 |
| 1981 | 36 | 0 |
| 1982 | 28 | 0 |
| 1983 | 24 | 0 |
| 1984 | 25 | 0 |
| 1985 | 35 | 0 |
| 1986 | 34 | 0 |
| 1987 | 41 | 0 |
| 1988 | 30 | 0 |
| 1989 | 41 | 0 |
| 1990 | 33 | 0 |
| 1991 | 22 | 0 |
| 1992 | 30 | 0 |
| 1993 | 49 | 0 |
| 1994 | 35 | 0 |
| 1995 | 57 | 0 |
| 1996 | 87 | 0 |
| 1997 | 74 | 0 |
| 1998 | 75 | 0 |
| 1999 | 77 | 0 |
| 2000 | 68 | 0 |
| 2001 | 80 | 18 |
| 2002 | 92 | 94 |
| 2003 | 92 | 143 |
| 2004 | 75 | 169 |
| 2005 | 67 | 160 |
| 2006 | 81 | 127 |
| 2007 | 88 | 144 |
| 2008 | 83 | 136 |
| 2009 | 80 | 143 |
| 2010 | 88 | 181 |
| 2011 | 101 | 114 |
| 2012 | 117 | 108 |
| 2013 | 114 | 113 |
| 2014 | 129 | 148 |
| 2015 | 126 | 152 |
| 2016 | 96 | 121 |
| 2017 | 107 | 112 |
| 2018 | 89 | 102 |
| 2019 | 87 | 100 |
| 2020 | 77 | 113 |
| 2021 | 82 | 100 |
| 2022 | 68 | 94 |
| 2023 | 53 | 126 |
| 2024 | 41 | 89 |
| 2025 | 58 | 79 |
| 2026 | 46 | 49 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C07D 217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems: with hetero atoms1,721
- C07D 217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems: with only hydrogen1,416
- C07D 217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems: with radicals, substituted758
Recent patents
- NAMPT modulators29 Sep 2026US 12,747,203 B2Cytokinetics, Inc.
- N-heteroarylalkyl-2-(heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists22 Sep 2026US 12,741,957 B2Takeda Pharmaceutical Company Limited
- Process for the preparation of bromodomain inhibitor8 Sep 2026US 12,729,183 B2Celgene Quanticel Research, Inc.
- Tetrahydroisoquinoline compound as potassium channel modulator and preparation and application thereof11 Aug 2026US 12,703,687 B2Shanghai Zhimeng Biopharma, Inc.
- Rock inhibitors and uses thereof28 Jul 2026US 12,692,234 B2Alcon Inc.
- Bicyclic compounds8 Oct 2026US 2026/0308114 A1Vivace Therapeutics, Inc.
- Usp30 inhibitors and uses thereof1 Oct 2026US 2026/0297026 A1Vincere Biosciences, Inc.
- Rock inhibitors and uses thereof1 Oct 2026US 2026/0297033 A1Alcon Inc.
- Modulators of sortilin activity24 Sep 2026US 2026/0285802 A1
- Aryl hydrocarbon receptor agonist prodrugs and methods of use thereof10 Sep 2026US 2026/0263431 A1Allianthera Boston Inc.
Most cited
By later US patents
- Color-safe bleach boosters, compositions and laundry methods employing same297US 5,576,282 AThe Procter & Gamble Company · 1996
- Heterocyclic compounds useful as inhibitors of tyrosine kinases202US 6,506,769 B2Boehringer Ingelheim Pharmaceuticals, Inc. · 2003
- Heterocyclic compounds useful as inhibitors of tyrosine kinases190US 6,770,639 B2Boehringer Ingelheim Pharmaceuticals, Inc. · 2004
- Retroviral protease inhibiting compounds159US 5,142,056 AAbbott Laboratories · 1992
- Modulators of ATP-binding cassette transporters157US 7,495,103 B2Vertex Pharmaceuticals Incorporated · 2009